Breaking News Instant updates and real-time market news.

RL

Ralph Lauren

$78.15

(0.00%)

, CBS

CBS

$64.52

(0.00%)

09:21
08/08/17
08/08
09:21
08/08/17
09:21

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Ralph Lauren (RL), up 8.3%... CBS (CBS), up 1.1%... Michael Kors (KORS), up 17.9%... Endo (ENDP), up 3.8%. DOWN AFTER EARNINGS: CVS Health (CVS), down 1.4%... Wayfair (W), down 1.3%... SeaWorld (SEAS), down 19.5%... Dean Foods (DF), down 13.2%.

RL

Ralph Lauren

$78.15

(0.00%)

CBS

CBS

$64.52

(0.00%)

KORS

Michael Kors

$37.23

(0.00%)

ENDP

Endo

$9.31

-0.07 (-0.75%)

CVS

CVS Health

$79.12

(0.00%)

W

Wayfair

$80.57

(0.00%)

SEAS

SeaWorld

$13.61

(0.00%)

DF

Dean Foods

$14.97

(0.00%)

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 10

    Aug

  • 17

    Aug

  • 07

    Sep

  • 21

    Sep

  • 22

    Sep

RL Ralph Lauren
$78.15

(0.00%)

07/18/17
NEED
07/18/17
INITIATION
NEED
Hold
Ralph Lauren initiated with a Hold at Needham
07/17/17
BUCK
07/17/17
INITIATION
Target $68
BUCK
Neutral
Ralph Lauren assumed with a Neutral at Buckingham
Buckingham analyst Eric Tracy assumed coverage of Ralph Lauren with a Neutral rating and $68 price target.
05/25/17
TIGR
05/25/17
INITIATION
TIGR
Neutral
Ralph Lauren initiated with a Neutral at Tigress Financial
Tigress analyst Ivan Feinseth initiated Ralph Lauren with a Neutral saying business performance continues to deteriorate at a rapid pace due to changes in consumer preference and retail industry headwinds.
04/20/17
OTRG
04/20/17
DOWNGRADE
OTRG
Negative
Ralph Lauren downgraded to Negative from Mixed at OTR Global
OTR Global downgraded Ralph Lauren to Negative saying checks indicate US outlets were hurt by a downturn in traffic and late winter storms in Q4 and orders for July-September are flat to down year-over-year among woman buyers.
CBS CBS
$64.52

(0.00%)

05/15/17
LOOP
05/15/17
NO CHANGE
Target $76
LOOP
Buy
CBS in 'enviable position' ahead of upfront presentation, says Loop Capital
Loop Capital analyst David Miller noted that CBS will finish as the number one network in total viewers for the fourteenth time in fifteen years when the 2016-2017 broadcast season ends this month and that the company's flagship network has no "glaring weakness" within any day or day-part. This makes CBS the one broadcast or cable network that has real leverage over media buyers as "upfront" negotiations begin next week, said Miller, who keeps a Buy rating and $76 price target on CBS shares.
05/19/17
RBCM
05/19/17
NO CHANGE
RBCM
CBS is predator and prey,' says RBC Capital
As the situation deteriorates for media companies due to accelerating cord cutting and weak ad trends, RBC Capital analyst Steven Cahall thinks that companies in the sector will look to consolidate.He believes that CBS (CBS) could buy Lionsgate (LGF.A,LGF.B) in a deal that would be 5% accretive and be viewed favorably by the market or the TV network could be acquired by Verizon (VZ). However, the analyst thinks the most likely scenario is an acquisition of Viacom (VIAB) by CBS.
06/27/17
PIPR
06/27/17
NO CHANGE
Target $75
PIPR
Overweight
CBS profits should expand by 53% by 2020, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says his analysis indicates CBS's profits should expand by 53% by 2020, with margins improving to 27% from 22%, as the company repositions itself as a content monetization engine versus its ad-dependent past. He notes that his estimates over the next four years are ahead of consensus. The analyst sees a "great entry point ahead of a number of catalysts" and keeps an Overweight rating on CBS shares with a $75 price target.
07/10/17
JEFF
07/10/17
NO CHANGE
Target $71
JEFF
Buy
CBS shares are undervalued, says Jefferies
CBS will be increasingly viewed as a multi-platform content creator rather than simply "the network," Jefferies analyst John Janedis tells investors in a research note. The analyst believes that CBS by 2020 will generate an incremental $2.00-plus per share in earnings from retrans, Showtime over-the-top and All Access. He views the stock as undervalued at current levels and keeps a Buy rating on the name with a $71 price target.
KORS Michael Kors
$37.23

(0.00%)

07/10/17
MKMP
07/10/17
INITIATION
Target $26
MKMP
Sell
Michael Kors initiated with a Sell at MKM Partners
MKM Partners initiated Michael Kors with a Sell and a $26 price target.
06/01/17
UBSW
06/01/17
NO CHANGE
Target $55
UBSW
Buy
Michael Kors store closures positive for Coach, says UBS
UBS analyst Michael Binetti noted Michael Kors (KORS) announced plans to start closing stores and it is assumed they will be skewed to North America. The analyst believes Michael Kors has been the number one competitive pressure for Coach (COH) over the past five years so its decision to close stores now relieves the company of its number one headwind. He now believes Coach is well positioned as a market share gainer. Binetti reiterated his Buy rating and $55 price target on Coach shares.
07/31/17
07/31/17
DOWNGRADE
Target $45

Hold
Coach downgraded to Hold from Buy at Jefferies
Jefferies analyst Randal Konik downgraded Coach (COH) to Hold citing valuation. The company's recovery is playing out, "but everyone knows it," Konik tells investors in a research note. The analyst lowered his price target for Coach shares to $45 from $53 and recommends buying shares of Michael Kors (KORS), where he feels the valuation and expectations are lower.
06/01/17
ADAM
06/01/17
NO CHANGE
Target $33
ADAM
Hold
Michael Kors guidance underscores broader challenges ahead, says Canaccord
Canaccord analyst Camilo Lyon noted Michael Kors beat Q4 estimates but said its weaker guidance underscores the broader challenges ahead for the company. Lyon said the company is finally taking aggressive course-correcting action to enhance the brand's position along with cost-savings. The analyst said the macro challenges in the U.S. and Europe remain and there is significant execution risk at hand. Lyon maintained his Hold rating and lowered his price target to $33 from $38 on Michael Kors shares.
ENDP Endo
$9.31

-0.07 (-0.75%)

06/09/17
06/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Neutral from Buy at Citi with analyst Mark May saying a slower than expected roll-out of new platforms and channels like self-serve is slowing down the pace of monetization growth. 2. Domino's Pizza (DPZ) downgraded to Neutral from Buy at Longbow with analyst Alton Stump saying his checks indicate second quarter domestic franchised comparables are up 6.25%-6.75%, versus consensus of 7.4%, and recommends investors take a pause on putting new money to work given recent share strength. 3. Nordstrom (JWN) downgraded to Neutral from Buy at Guggenheim with analyst Michael Binetti saying he does not see much further upside potential, even in a leveraged buyout scenario. The analyst believes a going private buyer could only pay $46 per share to generate a 10% internal rate of return. 4. Cantel Medical (CMD) downgraded to Hold from Buy at Benchmark with analyst Raymond Myers saying that he is increasingly concerned that its comparisons become tougher in the next two quarters. 5. Endo (ENDP) downgraded to Hold following Opana ER removal from market at Stifel with analyst Annabel Samimy saying Endo's recovery "just got harder" following the FDA's request for the company to voluntarily remove Opana ER from the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/09/17
WBLR
06/09/17
NO CHANGE
WBLR
FDA action on Opana a positive for Collegium, says William Blair
William Blair analyst Tim Lugo views FDA request to remove Endo's (ENDP) Opana ER from the market as a positive for Collegium Pharmaceutical (COLL). The analyst believes Collegium's Xtampza ER has a "best-in-class abuse-deterrent profile." He thinks the drug's scripts could "meaningfully ramp up in the near term." Lugo keeps an Outperform rating on Collegium.
06/16/17
CANT
06/16/17
INITIATION
Target $12
CANT
Neutral
Endo initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Endo International with a Neutral rating and $12 price target.
07/24/17
JANY
07/24/17
NO CHANGE
Target $4
JANY
Buy
BioDelivery Sciences price target raised to $4 from $3 at Janney Capital
Janney Capital analyst Ken Trbovich sees multiple reasons to expect BioDelivery Sciences' Belbuca growth above current levels, including the continued maturing of its newer sales people, the opportunity to secure Medicare coverage contracts and Endo's (ENDP) recent decision to remove Opana ER from the market. He raised his fair value estimate on BioDelivery to $4 from $3 and keeps a Buy rating on the stock.
CVS CVS Health
$79.12

(0.00%)

06/27/17
LEER
06/27/17
NO CHANGE
Target $90
LEER
Outperform
CVS gained largest PBM share in 2017 selling season, says Leerink
Leerink analyst David Larsen says his firm's recently published Pharmacy Benefit Manager survey shows that CVS Health is the largest share gainer in the 2017 selling season. The company is poised to win incremental PBM and Specialty Pharmacy share, while the Optum and Cigna deals will start to benefit retail volumes in the near-term, Larsen tells investors in a research note. He keeps an Outperform rating on CVS shares with a $90 price target.
06/27/17
NEED
06/27/17
INITIATION
NEED
Hold
CVS Health initiated with a Hold at Needham
Needham analyst Kevin Caliendo initiated CVS Health with a Hold.
06/28/17
06/28/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altaba (AABA) initiated with an Overweight at JPMorgan. 2. Aetna (AET) and Humana (HUM) were initiated with a Buy at Citi. The firm also added Aetna to its Focus List. 3. CVS Health (CVS) and Walgreens Boots Alliance (WBA) were initiated with a Hold at Needham. 4. Oaktree Capital (OAK) initiated with a Hold at Jefferies. 5. General Motors (GM) resumed with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
W Wayfair
$80.57

(0.00%)

07/13/17
BUCK
07/13/17
NO CHANGE
Target $95
BUCK
Buy
Wayfair price target raised to $95 from $72 at Buckingham
Buckingham analyst Kelly Halsor reiterates a Buy rating on Wayfair and raised her price target for the shares to $95 from $72. The analyst believes a higher valuation multiple is justified given the reacceleration of direct revenue growth in Q2 and increased acquisition activity by big box retailers.
08/03/17
WOLF
08/03/17
INITIATION
Target $88
WOLF
Outperform
Wayfair initiated with an Outperform at Wolfe Research
After the market close last night, Wolfe Research analyst Adrienne Yih started Wayfair with an Outperform rating and $88 price target, calling it the home goods market's "premiere e-commerce growth play."
08/04/17
OPCO
08/04/17
NO CHANGE
Target $88
OPCO
Outperform
Wayfair price target raised to $88 from $80 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target for Wayfair to $88 ahead of the company's Q2 results on August 8. Industry data has remained solid while key internal initiatives at Wayfair continue to take hold, Nagel tells investors in a pre-earnings research note. He's "optimistic" that further indications of elevated sales growth should prove another positive, near-term catalyst for shares. Nagel stays Outperform-rated on Wayfair. The online retailer closed yesterday up $3.50 to $77.33.
06/30/17
PIPR
06/30/17
NO CHANGE
Target $87
PIPR
Overweight
Piper analysis shows Wayfair Direct Retail revenue above guidance
Piper Jaffray analyst Peter Keith says his firm's proprietary analysis of Google search trends indicates Wayfair Direct Retail revenue growth of 46% for Q2 versus guidance of 34%-37% and consensus of 40%. The "strong" Direct Retail revenue growth reacceleration is being driven by increased product offerings, exclusivity of products, strategic investments in logistics and supply chain, and increased customer satisfaction due to positive delivery execution, Keith tells investors in a research note. He raised his Q2 revenue estimate to $1.084B, above the consensus of $1.056B, and reiterates an Overweight rating on Wayfair with an $87 price target.
SEAS SeaWorld
$13.61

(0.00%)

08/03/17
08/03/17
DOWNGRADE
Target $15

Market Perform
SeaWorld downgraded to Market Perform ahead of Q2 results at FBR Capital
FBR Capital analyst Barton Crockett downgraded SeaWorld to Market Perform from Outperform and lowered his price target for the shares to $15 from $20. June data for the San Diego park suggest the new attraction lineup and orca show did not reverse sluggish revenue trends, Crockett tells investors in a research note. He's cautious into the Q2 earnings report. The shares in afternoon trading are down 30c to $13.77.
08/03/17
08/03/17
DOWNGRADE

Market Perform
SeaWorld downgraded to Market Perform from Outperform at FBR Capital
08/02/17
STFL
08/02/17
NO CHANGE
STFL
SeaWorld CFO change positive, says Stifel
After SeaWorld announced that its CFO, Peter Crage, would leave the company, Stifel analyst Steven M. Wieczynski says the news is positive. The analyst reports that investors believe that Crage did not effectively manage expectations for the company's results. Additionally, the analyst is pleased that the company's CEO will be able to appoint the CFO of his choice. The analyst keeps a $23 price target and a Buy rating on the shares.
08/01/17
RHCO
08/01/17
NO CHANGE
RHCO
SeaWorld can sell itself or monetize regional parks, says SunTrust
After SeaWorld rallied 7% following a report which stated that the company had hired a strategic adviser, SunTrust analyst Michael A. Swartz says that the company can either sell itself or monetize its regional parks. He estimates that the latter scenario could generate $800M-$1B. The analyst notes that two major shareholders which own a total of roughly 35% of the company could be an obstacle to any deal, and he says that the report, if true, will make investors question the success of its current turnaround plan. He keeps a $22 price target and a Buy rating on the stock.
DF Dean Foods
$14.97

(0.00%)

08/08/17
SPHN
08/08/17
DOWNGRADE
SPHN
Equal Weight
Dean Foods downgraded to Equal Weight from Overweight at Stephens
07/27/17
07/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Market Perform from Outperform at Leerink with analyst Seamus Fernandez citing the company's "continued reliance on externalization profits and deteriorating earnings quality." 2. F5 Networks (FFIV) was downgraded to Market Perform from Outperform at Wells Fargo and to Perform from Outperform at Oppenheimer. 3. UMC (UMC) was downgraded to Underperform from Neutral at Credit Suisse and to Underperform from Market Perform at Bernstein. 4. U.S. Steel (X) and AK Steel (AKS) were downgraded to Neutral from Buy at Longbow. 5. Dean Foods (DF) downgraded to Underperform from Market Perform at Bernstein with analyst Alexia Howard saying she believes that retailers are increasingly using cheap, private label milk in order to compete with low price competitors. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/17
JPMS
08/08/17
DOWNGRADE
JPMS
Neutral
Dean Foods downgraded to Neutral from Overweight at JPMorgan
07/27/17
BERN
07/27/17
DOWNGRADE
BERN
Underperform
Dean Foods downgraded to Underperform from Market Perform at Bernstein
Bernstein analyst Alexia Howard downgraded Dean Foods as she believes that retailers are increasingly using cheap, private label milk in order to compete with low price competitors. The analyst expects this change to last longer than in previous cycles. Target to $13 from $18.

TODAY'S FREE FLY STORIES

BCO

Brink's

$61.25

-0.85 (-1.37%)

12:22
12/10/18
12/10
12:22
12/10/18
12:22
Conference/Events
Brink's management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

QCOM

Qualcomm

$57.75

1.75 (3.13%)

, AAPL

Apple

$164.67

-3.7 (-2.20%)

12:20
12/10/18
12/10
12:20
12/10/18
12:20
Recommendations
Qualcomm, Apple analyst commentary  »

Injunction may be first…

QCOM

Qualcomm

$57.75

1.75 (3.13%)

AAPL

Apple

$164.67

-3.7 (-2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTRI

Nutrisystem

$44.15

9.96 (29.13%)

12:17
12/10/18
12/10
12:17
12/10/18
12:17
Downgrade
Nutrisystem rating change  »

Nutrisystem downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/10/18
12/10
12:17
12/10/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLD

TopBuild

$46.22

-0.96 (-2.03%)

12:16
12/10/18
12/10
12:16
12/10/18
12:16
Conference/Events
TopBuild management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/10/18
12/10
12:16
12/10/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$49.62

-2.44 (-4.69%)

12:15
12/10/18
12/10
12:15
12/10/18
12:15
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CCK

Crown Holdings

$47.82

-0.22 (-0.46%)

12:14
12/10/18
12/10
12:14
12/10/18
12:14
Conference/Events
Crown Holdings to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRDXF

Nordex

$0.00

(0.00%)

12:13
12/10/18
12/10
12:13
12/10/18
12:13
Upgrade
Nordex rating change  »

Nordex upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:10
12/10/18
12/10
12:10
12/10/18
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

KO

Coca-Cola

$48.84

-0.24 (-0.49%)

12:08
12/10/18
12/10
12:08
12/10/18
12:08
Periodicals
Coca-Cola hires broker to sell iconic Fifth Avenue building, Bloomberg says »

Coca-Cola has enlisted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 18

    Dec

  • 03

    Mar

DLAKY

Lufthansa

$0.00

(0.00%)

, EADSY

Airbus

$0.00

(0.00%)

12:07
12/10/18
12/10
12:07
12/10/18
12:07
Periodicals
Avianca CEO wants to cut Airbus order by as much as half, Reuters says »

Avianca Holdings (AVH)…

DLAKY

Lufthansa

$0.00

(0.00%)

EADSY

Airbus

$0.00

(0.00%)

AVH

Avianca

$4.91

-0.39 (-7.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$165.25

-3.12 (-1.85%)

, QCOM

Qualcomm

$58.05

2.05 (3.66%)

12:06
12/10/18
12/10
12:06
12/10/18
12:06
OnTheFly
Fly Intel: Wall Street's top stories at midday »

The averages were…

AAPL

Apple

$165.25

-3.12 (-1.85%)

QCOM

Qualcomm

$58.05

2.05 (3.66%)

FB

Facebook

$140.74

3.32 (2.42%)

GPRO

GoPro

$4.94

-0.04 (-0.80%)

TVPT

Travelport

$15.68

0.275 (1.79%)

NTRI

Nutrisystem

$44.14

9.95 (29.10%)

TVTY

Tivity Health

$28.53

-12.07 (-29.73%)

XPER

Xperi

$18.34

5.54 (43.28%)

SSNLF

Samsung

$0.00

(0.00%)

MDRX

Allscripts

$10.15

0.66 (6.95%)

MGNX

MacroGenics

$12.00

-4.44 (-27.01%)

CRZO

Carrizo Oil & Gas

$14.69

-1.2 (-7.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 06

    Jan

KZR

Kezar Life Sciences

$27.79

0.41 (1.50%)

12:05
12/10/18
12/10
12:05
12/10/18
12:05
Conference/Events
Kezar Life Sciences management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

T

AT&T

$29.50

-0.64 (-2.12%)

12:05
12/10/18
12/10
12:05
12/10/18
12:05
Options
AT&T call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 20

    Mar

BC

Brunswick

$49.53

-0.05 (-0.10%)

12:02
12/10/18
12/10
12:02
12/10/18
12:02
Conference/Events
Brunswick management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

AJG

Arthur J. Gallagher

$73.87

-0.74 (-0.99%)

12:01
12/10/18
12/10
12:01
12/10/18
12:01
Hot Stocks
Arthur J. Gallagher acquires Captive Insurance Company Design and Operations »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

JP

Jupai Holdings

$5.06

-0.94 (-15.67%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Jupai Holdings falls -15.8% »

Jupai Holdings is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSC

Global Geoscience

$23.90

(0.00%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Global Geoscience falls -16.2% »

Global Geoscience is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPX

Marine Products

$18.19

-3.4 (-15.75%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Marine Products falls -18.3% »

Marine Products is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPER

Xperi

$18.39

5.59 (43.67%)

, SSNLF

Samsung

$0.00

(0.00%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Recommendations
Xperi, Samsung analyst commentary  »

Xperi settlement removes…

XPER

Xperi

$18.39

5.59 (43.67%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Jan

FAZ

Direxion Financial Bear 3x

$12.50

0.67 (5.66%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Direxion Financial Bear 3x rises 5.8% »

Direxion Financial Bear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCUS

Arcus Biosciences

$13.15

0.9 (7.35%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Arcus Biosciences rises 8.1% »

Arcus Biosciences is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYX

Systemax

$29.66

3.57 (13.68%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Systemax rises 13.9% »

Systemax is up 13.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

GOOG

Alphabet

$1,034.54

-1.98 (-0.19%)

, GOOGL

Alphabet Class A

$1,044.62

-2.37 (-0.23%)

11:58
12/10/18
12/10
11:58
12/10/18
11:58
Periodicals
Google acquires Indian app developer Sigmoid Labs, VB reports »

Google has acquired…

GOOG

Alphabet

$1,034.54

-1.98 (-0.19%)

GOOGL

Alphabet Class A

$1,044.62

-2.37 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.